Abstract

Bibliographic details

Liubao P, Xiaomin W, Chongqing T, Karnon J, Gannong C, Jianhe L, Wei C, Xia L, Junhua C.  Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide. PharmacoEconomics 2009; 27(10): 873-886

Status

This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Indexing status

Subject indexing assigned by NLM

Index terms

Antineoplastic Combined Chemotherapy Protocols /economics /therapeutic use; Breast Neoplasms /economics /therapy; Chemotherapy, Adjuvant /economics; China; Clinical Trials as Topic; Cost-Benefit Analysis; Cyclophosphamide /administration & dosage; dosage; Doxorubicin /administration & dosage; Female; Humans; Markov Chains; Middle Aged; Quality-Adjusted Life Years; Taxoids /administration & dosage